Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30108998 | 0.84 | CYP2D6 (0.39) | CYP2D6ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL30108855 | 0.83 | TP53 (0.42) | ALDH1A1TSHRKDM4EGAA | |
| SCHEMBL30108918 | 0.82 | TSHR (0.34) | ALDH1A1SMN1; SMN2TSHRLMNAMEN1 | |
| SCHEMBL24704071 | 0.80 | KMT2A (0.43) | CYP2D6ALDH1A1TSHRLMNAKDM4E | |
| SCHEMBL30108992 | 0.78 | ALDH1A1 (0.34) | ALDH1A1KDM4EMEN1KMT2AEPHX2 | |
| SCHEMBL30108966 | 0.75 | PRKCA (0.39) | ALDH1A1TSHRMEN1KMT2AEPHX2 | |
| SCHEMBL30108879 | 0.67 | TSHR (0.33) | ALDH1A1SMN1; SMN2TSHREPHX2 | |
| SCHEMBL30063684 | 0.66 | CYP2D6 (0.39) | CYP2D6ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL30108848 | 0.66 | TP53 (0.34) | — | |
| SCHEMBL10081206 | 0.64 | CYP2D6 (0.46) | CYP2D6ALDH1A1SMN1; SMN2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101833-B1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | SHINETSU CHEMICAL CO (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-11731930-B2 | Processes for preparing a (1,2-dimethyl-3-methylenecyclopentyl)acetate compound and (1,2-dimethyl-3-methylenecyclopentyl)acetaldehyde | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230002305-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| EP-4101833-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | Shin-Etsu Chemical Co., Ltd. (JP) | 2022-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731930-B2 | Processes for preparing a (1,2-dimethyl-3-methylenecyclopentyl)acetate compound and (1,2-dimethyl-3-methylenecyclopentyl)acetaldehyde | ADH1C, AKR1C4, AKR1C2 | CYP2D6 34/4885ALDH1A1 10/4885SMN1; SMN2 3469/4885 |
| US-20230002305-A1 | PROCESSES FOR PREPARING A (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETATE COMPOUND AND (1,2-DIMETHYL-3-METHYLENECYCLOPENTYL)ACETALDEHYDE | ADH1C, AKR1C4, AKR1C2 | CYP2D6 34/4885ALDH1A1 10/4885SMN1; SMN2 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.